Browse MYL9

Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF13405 EF-hand domain
PF13833 EF-hand domain pair
Function

Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation. Implicated in cytokinesis, receptor capping, and cell locomotion.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0006936 muscle contraction
GO:0006937 regulation of muscle contraction
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0030168 platelet activation
GO:0034109 homotypic cell-cell adhesion
GO:0044057 regulation of system process
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0070527 platelet aggregation
GO:0090257 regulation of muscle system process
Molecular Function GO:0008307 structural constituent of muscle
GO:0017022 myosin binding
GO:0032036 myosin heavy chain binding
Cellular Component GO:0001725 stress fiber
GO:0005859 muscle myosin complex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0016460 myosin II complex
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030018 Z disc
GO:0031674 I band
GO:0032432 actin filament bundle
GO:0042641 actomyosin
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
GO:0097517 contractile actin filament bundle
> KEGG and Reactome Pathway
 
KEGG hsa04022 cGMP-PKG signaling pathway
hsa04024 cAMP signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04510 Focal adhesion
hsa04530 Tight junction
hsa04670 Leukocyte transendothelial migration
hsa04810 Regulation of actin cytoskeleton
hsa04921 Oxytocin signaling pathway
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928663: EPHA-mediated growth cone collapse
R-HSA-397014: Muscle contraction
R-HSA-195258: RHO GTPase Effectors
R-HSA-5627117: RHO GTPases Activate ROCKs
R-HSA-5625900: RHO GTPases activate CIT
R-HSA-5627123: RHO GTPases activate PAKs
R-HSA-5625740: RHO GTPases activate PKNs
R-HSA-400685: Sema4D in semaphorin signaling
R-HSA-416572: Sema4D induced cell migration and growth-cone collapse
R-HSA-373755: Semaphorin interactions
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-445355: Smooth Muscle Contraction
Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYL9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYL9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYL9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.030.0271
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0990.708
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9670.622
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5970.487
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6960.803
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4710.895
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.30.585
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8420.614
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3290.862
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1260.669
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2820.6
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.320.0843
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYL9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYL9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYL9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYL9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYL9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYL9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYL9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYL9
Namemyosin, light chain 9, regulatory
Aliases MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYL9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.